Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$34.40 USD
-0.78 (-2.22%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $34.38 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HRMY 34.40 -0.78(-2.22%)
Will HRMY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HRMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRMY
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
HRMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
5 High Earnings Yield Stocks to Tap Into Value Investing Gains
Other News for HRMY
Harmony Biosciences Holdings Inc (HRMY) to Announce Q2 2025 Financial Results | HRMY stock news
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 | HRMY ...
Truist Securities Initiates Coverage on Harmony Biosciences (HRMY) with Buy Rating | HRMY Stock News
Truist Initiates Buy Rating for Harmony Biosciences (HRMY) with Promising Growth Prospects | ...
Harmony Biosciences initiated with bullish view at Truist, here's why